Cyclooxyoenase-2-dependent and thromboxane-dependent vascular and bronchial responses are regulated via p38 mitogen-activated protein kinase in control and endotoxin-primed rat lungs

Laboratory Investigation

Volumn 83, Issue 3, 2003, Pages 333-347

  Ermert, Monika ^a   Kuttner, Daniel ^a   Eisenhardt, Nils ^a   Dierkes, Christian ^a   Seeger, Werner ^a   Ermert, Leander ^a,b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Inst fuer Anatomie und Zellbiologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONIC ACID; BACTERIUM LIPOPOLYSACCHARIDE; CYCLOOXYGENASE 2; ENDOTOXIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SC 68376; THROMBOXANE; THROMBOXANE B2; UNCLASSIFIED DRUG; 2 METHYL 4 PHENYL (4 PYRIDYL)OXAZOLE; 2-METHYL-4-PHENYL-(4-PYRIDYL)OXAZOLE; BACTERIAL TOXIN; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; ISOENZYME; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; OXAZOLE DERIVATIVE; PROSTAGLANDIN SYNTHASE; PYRIDINE DERIVATIVE; SALMONELLA TOXIN;

ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CELL TYPE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; ISOLATED LUNG; LUNG DISEASE; LUNG EDEMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ANIMAL; BRONCHOSPASM; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IMMUNOLOGY; IN VITRO STUDY; LUNG; LUNG CIRCULATION; METABOLISM; PERFUSION; SPRAGUE DAWLEY RAT; VASOCONSTRICTION;

ANIMALS; BACTERIAL TOXINS; BRONCHOCONSTRICTION; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXINS; ENZYME INHIBITORS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LIPOPOLYSACCHARIDES; LUNG; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; OXAZOLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERFUSION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PULMONARY CIRCULATION; PULMONARY EDEMA; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; THROMBOXANES; VASOCONSTRICTION;

EID: 0037364184     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000059924.47118.88     Document Type: Article

References (54)

1. Barnes PJ (2001). Future advances in COPD therapy. Respiration 68:441-448.
2. Brigham KL and Meyrick B (1986). Endotoxin and lung injury. Am Rev Respir Dis 133:913-927.
3. Carter AB, Monick MM, and Hunninghake GW (1999). Both Erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol 20:751-758.
4. Chen BC, Chen YH, and Lin WW (1999). Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and Cox-2 expression in J774 macrophages. Immunology 97:124-129.
5. Chow JC, Young DW, Golenbock DT, Christ WJ, and Gusovsky F (1999). Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274(16):10689-10692.
6. Cuenda A, Cohen P, Buée-Scherrer V, and Goedert M (1997). Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6): Comparison of the specificities of SAPK3 and SAPK2 (RK/p38). EMBO J 16(2):295-305.
7. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, and Lee JC (1995). SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364:229-233.
8. Dean JLE, Brook M, Clark AR, and Saklatvala J (1999). p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 274(1):264-269.
9. Ermert L, Ermert M, Althoff A, Merkle M, Grimminger F, and Seeger W (1998a). Vasculatory prostanoid generation proceeds via cyclooxygenase-2 in non-inflamed rat lungs. J Pharmacol Exp Ther 286:1309-1314.
10. Ermert L, Ermert M, Duncker HR, Grimminger F, and Seeger W (2000a). In-situ localization and regulation of thromboxane A2 synthase in normal and LPS-primed lungs. Am J Physiol Cell Mol Physiol 278:L744-L753.
11. Ermert L, Ermert M, Goppelt-Struebe M, Walmrath D, Grimminger F, Steudel W, Ghofrani HA, Homberger C, Duncker HR, and Seeger W (1998b). Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. Am J Respir Cell Mol Biol 18:479-488.
12. Ermert L, Ermert M, Merkle M, Goppelt-Struebe M, Duncker HR, Grimminger F, and Seeger W (2000b). Rat pulmonary cyclooxygenase-2 expression in response to endotoxin challenge: Differential regulation in the various types of cells in the lung. Am J Pathol 156(4):1275-1287.
13. Ermert L, Hocke ACH, Duncker HR, Seeger W, and Ermert M (2001). Comparison of different detection methods in quantitative microdensitometry. Am J Pathol 158:407-417.
14. Ermert M, Merkle M, Mootz R, Grimminger F, Seeger W, and Ermert L (2000c). Endotoxin priming of the cyclooxygenase-2-thromboxane axis in isolated rat lungs. Am J Physiol Lung Cell Mol Physiol 278:L1195-L1203.
15. Ermert M, Ruppert C, Guenther A, Duncker HR, Seeger W, and Ermert L (2002). Cell-specific nitric oxide synthaseisoenzyme expression and regulation in response to endotoxin in intact rat lungs. Lab Invest 82:425-441.
16. Feng GJ, Goodridge HS, Harnett MM, Wei XQ, Nikolaev AV, Higson AP, and Liew FY (1999). Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J Immunol 163:6403-6412.
17. Guan Z, Buckman SY, Pentland AP, Templeton DJ, and Morrison AR (1998). Induction of cyclooxygenase-2 by the activated MEKK1 → SEK2/MKK4 → p38 mitogen-activated protein kinase pathway. J Biol Chem 273(21):12901-12908.
18. Harris RC and Breyer MD (2001). Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 281:F1-F11.
19. Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, and Goyert SM (1996). Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 4:407-414.
20. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takea K, and Akira S (1999). Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol 162:3749-3752.
21. Hwang D, Jang BC, Yu G, and Boudreau M (1997). Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-κB signaling pathways in macrophages. Biochem Pharmacol 54:87-96.
22. Ingalls RR and Golenbock DT (1995). CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med 181:1473-1479.
23. Jarrar D, Wang P, Song GY, Cioffi WG, Bland KI, and Chaudry IH (2000). Inhibition of tyrosine kinase signaling after trauma-hemorrhage: A novel approach for improving organ function and decreasing susceptibility to subsequent sepsis. Ann Surg 231(3):399-407.
24. Kirschning CJ and Bauer S (2001). Toll-like receptors: Cellular signal transducers for exogenous molecular patterns causing immune responses. Int J Med Microbiol 291(4):251-260.
25. Kristof AS, Marks-Konczalik J, and Moss J (2001). Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation. J Biol Chem 276(11):8445-8452.
26. Kumar S, Jiang MS, Adams JL, and Lee JC (1999). Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun 263:825-831.
27. Laporte JD, Moore PE, Lahiri T, Schwartzman IN, Panettieri RA Jr, and Shore SA (2000). p38 MAP kinase regulates IL-1b responses in cultured airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 279:L932-L941.
28. Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, and Clark A (2000). Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol Cell Biol 20(12):4265-4274.
29. Lee JC, Kassis S, Kumar S, Badger A, and Adams JL (1999). p38 mitogen-activated protein kinase inhibitors: Mechanisms and therapeutic potentials. Pharmacol Ther 82(2-3):389-397.
30. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, and Adams JL (2000). Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47:185-201.
31. Liverton NJ, Butcher JW, Claiborne CF, Claremon DA, Libby BE, Nguyen KT, Pitzenberger SM, Selnick HG, Smith GR, Tebben A, Vacca JP, Varga SL, Agarwal L, Dancheck K, Forsyth AJ, Fletcher DS, Frantz B, Hanlon WA, Harper CF, Hofsess SJ, Kostura M, Lin J, Luell S, O'Neill EA, Orevillo CJ, Pang M, Parsons J, Rolando A, Sahly Y, Visco DM, and O'Keefe SJ (1999). Design and synthesis of potent, selective and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J Med Chem 42(12): 2180-2190.
32. Mason RJ and Williams MC (1991). Alveolar type II cells. In: Crystal RG and West JB, editors. The lung. New York: Raven Press, 235-246.
33. McLeish KR, Knall C, Ward RA, Gerwins P, Coxon PY, Klein JB, and Johnson GL (1998). Activation of mitogen-activated protein kinase cascades during priming of human neutrophils by TNF-α and GM-CSF. J Leukoc Biol 64:537-545.
34. Nahas N, Molski TFP, Fernandez GA, and Shaáfi RI (1996). Tyrosine phosphorylation and activation of a new mitogen-activated protein (MAP)-kinase cascade in human neutrophils stimulated with various agonists. Biochem J 318:247-253.
35. Newton R, Cambridge L, Stevens DA, Linday MA, and Barnes PJ (2000). The MAP kinase inhibitors PD098059, U0126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes. Br J Pharmacol 130:1353-1361.
36. Nick JA, Avdi NJ, Gerwins P, Johnson GL, and Worthen GS (1996). Activation of a p38 mitogen activated protein kinase in human neutrophils by lipopolysaccharide. J Immunol 156(12):4867-4875.
37. Nick JA, Avdi NJ, Young SK, Lehman LA, McDonald PP, Frasch SC, Billstrom MA, Henson PM, Johnson GL, and Worthen GS (1999). Selective activation and functional significance of p38α mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. J Clin Invest 103: 851-858.
38. O'Neill L (2001). Specificity in the innate response: Pathogen recognition by Toff-like receptor combinations. Trends Immunol 22(2):70.
39. Ono K and Han J (2000). The p38 signal transduction pathway: Activation and function. Cell Signal 12:1-13.
40. Paul A, Wilson S, Belham CM, Robinson CJM, Scott PH, Gould GW, and Plevin R (1997). Stress-activated protein kinases: Activation, regulation and function. Cell Signal 9(6): 403-410.
41. Pugin J, Schürer-Maly CC, Leturcq D, Moriatry A, Ulevitch RJ, and Tobias PS (1993). Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA 90:2744-2748.
42. Quinn D, Tager A, Joseph PM, Bonventre JV, Force T, and Hales CA (1999). Stretch-induced mitogen-activated protein kinase activation and interleukin-8 production in type II alveolar cells. Chest 116:89S-90S.
43. Qureshi S, Larivière L, Leveque G, Clermont S, Moore KJ, Gros P, and Malo D (1999). Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 189(4):615-625.
44. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, and Davis RJ (1995). Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270(13):7420-7426.
45. Rakhit RD, Kabir AN, Mockridge JW, Saurin A, and Marber MS (2001). Role of G proteins and modulation of p38 MAPK activation in the protection by nitric oxide against ischemiareoxygenation injury. Biochem Biophys Res Commun 286(5):995-1002.
46. Rao KM (2001). MAP kinase activation in macrophages. J Leukoc Biol 69(1):3-10.
47. Ridley SH, Dean JLE, Sarsfield SJ, Brook M, Clark AR, and Saklatvara J (1998). A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett 439:75-80.
48. Schwandner R, Dziarski R, Wesche H, Rothe M, and Kirsching CJ (1999). Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J Biol Chem 274(25):17406-17409.
49. Sherry B and Cerami A (1988). Cachectin/tumor necrosis factor exerts endocrine, paracrine and autocrine control of inflammatory responses. J Cell Biol 107:1269-1277.
50. Ulevitch RJ (1991). Recognition of bacterial endotoxin in biologic systems. Lab Invest 65:121-122.
51. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, and Mathison JC (1990). CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433.
52. Yang H, Young DW, Gusovsky F, and Chow JC (2000). Cellular events mediated by lipopolysaccharide-stimulated Toll-like receptor 4: MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J Biol Chem 275(27):20861-20866.
53. Yoshimura A, Lien E, Ingalls RR, Toumanen E, Dziarski R, and Golenbock D (1999). Recognition of gram-positive bacterial cell wall components by the innate immune system occurs via toll-like receptor 2. J Immunol 163:1-5.
54. Yoshinari D, Takeyoshi I, Kobayashi M, Koyama T, Iijima K, Ohwada S, Matsumoto K, and Morishita Y (2001). Effects of a p38 mitogen-activated protein kinase inhibitor as an additive to University of Wisconsin solution on reperfusion injury in liver transplantation. Transplantation 72(1):22-27.